Treatment of recurrent glioma remains a therapeutic challenge. Unprecedented high response rates associated with rapid clinical improvement have been observed. Despite the absence of definitive data and while definitive trial has not even been started, regulatory approval was requested. And while the United States Food and Drug Administration granted accelerated approval based on 2 small uncontrolled phase II trials, the European Medicines Agency rejected the application.
About this chapter
Cite this chapter as:Roger Stupp ;
Bevacizumab for Recurrent Glioma - A Personal View, Controversies in Neuro-Oncology Avastin and Malignant Gliomas (2010) 1: 133. https://doi.org/10.2174/978160805132811001010133
Bentham Science Publisher